Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
| ▸ | PRKDC | P78527 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.49 |
| ▸ | TUBB | P07437 | 2/20 | 0.49 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.49 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.49 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.49 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.49 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.49 |
| ▸ | TUBB2A | Q13885 | 2/20 | 0.49 |
| ▸ | TUBB8 | Q3ZCM7 | 2/20 | 0.49 |
| ▸ | TUBA3E | Q6PEY2 | 2/20 | 0.49 |
| ▸ | TUBA1A | Q71U36 | 2/20 | 0.49 |
| ▸ | TUBA1C | Q9BQE3 | 2/20 | 0.49 |
| ▸ | TUBB6 | Q9BUF5 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5583299 | 0.87 | ALDH1A1 (0.55) | ALDH1A1MAPTKDM4ECYP3A4ALOX15 | |
| SCHEMBL3398845 | 0.87 | ALDH1A1 (0.58) | ALDH1A1MAPTKDM4ECYP3A4ALOX15 | |
| SCHEMBL16689310 | 0.86 | ALDH1A1 (0.54) | ALDH1A1MAPTKDM4ECYP3A4ALOX15 | |
| SCHEMBL7016993 | 0.86 | ALDH1A1 (0.54) | ALDH1A1MAPTKDM4ECYP3A4ALOX15 | |
| SCHEMBL9348382 | 0.80 | ALDH1A1 (0.53) | ALDH1A1MAPTKDM4ECYP3A4ALOX15 | |
| SCHEMBL1318577 | 0.80 | ALDH1A1 (0.50) | ALDH1A1MAPTKDM4ECYP3A4ALOX15 | |
| SCHEMBL1447403 | 0.78 | TUBB4A (0.61) | ALDH1A1MAPTKDM4ECYP3A4ALOX15 | |
| SCHEMBL31337893 | 0.78 | TUBB4A (0.61) | ALDH1A1MAPTKDM4ECYP3A4ALOX15 | |
| Ethylene SCHEMBL10751755 | 0.78 | ALDH1A1 (0.47) | ALDH1A1MAPTKDM4ECYP3A4ALOX15 | |
| SCHEMBL3842938 | 0.77 | ERN1 (0.56) | ALDH1A1MAPTKDM4ECYP3A4ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1400510-B1 | CYCLIC DIAMINE COMPOUNDS HAVING FUSED-RING GROUPS | KOWA CO (JP) | 2010-08-18 | — | — | EP | disclosed |
| US-7135473-B2 | Cyclic diamine compound with condensed-ring groups | KOWA CO., LTD. (JP) | 2006-11-14 | — | — | US | disclosed |
| CN-1817863-A | 3-substituted 1,2,3.4-tetrahydro-quinazine derivative, its synthesis and use | SHANGHAI PHARMACEUTICAL INST C (CN) | 2006-08-16 | — | — | CN | disclosed |
| US-20040058913-A1 | Cyclic diamine compound with condensed-ring groups | KOWA CO., LTD. (JP) | 2004-03-25 | — | — | US | disclosed |
| EP-1400510-A1 | CYCLIC DIAMINE COMPOUNDS HAVING FUSED-RING GROUPS | Kowa Co., Ltd. (JP) | 2004-03-24 | — | — | EP | disclosed |
| US-6632810-B2 | Such as N,N'-bis((5,6,7-trimethoxynaphthalen-2-yl)methyl) piperazine, which has inhibitory effects on cell adhesion, for treatment of allergy, asthma, rheumatism, arteriosclerosis, and inflammation | KOWA CO., LTD. (JP) | 2003-10-14 | — | — | US | disclosed |
| US-20030060461-A1 | Cyclic diamine compound with condensed-ring groups | KOWA CO., LTD. (JP) | 2003-03-27 | — | — | US | disclosed |
| US-5296602-A | Condensing substituted ortho-halo- or ortho-aminobenzoic acid with meta-halo- or meta-aminoanisole, cyclizing, N-alkylating, de-O-methylating | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1994-03-22 | — | — | US | disclosed |
| WO-1992016509-A1 | MULTISUBSTITUTED 1-HYDROXY-9-ACRIDONES WITH ANTICANCER ACTIVITY | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1992-10-01 | — | — | WO | disclosed |
| CN-1016175-B | Imidazoquinoline antithrombin cardiotonic agents | BRISTOL MYERS CO (US) | 1992-04-08 | — | — | CN | disclosed |
| US-4668686-A | 1,3-DIHYDRO-2H-IMIDAZO/4,5-B/QUINOLINE-2-ONES | BRISTOL-MYERS COMPANY (US) | 1987-05-26 | — | — | US | disclosed |
| CN-86102747-A | The preparation method of imidazoquinoline antithombogehic cardiotonic agents | — | 1987-02-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058913-A1 | Cyclic diamine compound with condensed-ring groups | HRH4, HRH3, HRH1 | ALDH1A1 468/4885MAPT 4342/4885KDM4E 2052/4885 |
| US-20030060461-A1 | Cyclic diamine compound with condensed-ring groups | HRH4, HRH3, HRH1 | ALDH1A1 468/4885MAPT 4342/4885KDM4E 2052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.